The United States Insulin Pump Market is projected to grow from US$ 1.55 billion in 2024 to US$ 2.58 billion in 2033, with a ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the ...

Tandem Diabetes Care, Inc. , a global insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is ...

Tandem Diabetes Care (Nasdaq:TNDM) today announced the rollout of its latest automated insulin delivery system integration.

Tandem Diabetes has announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus ...

Earlier this year, Tandem Diabetes Care announced a voluntary correction for certain t:slim X2 insulin pumps after identifying a potential defect that could interrupt insulin delivery and pose health ...

Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) jumped 1.6% in the afternoon session after the ...

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.57, along with a high estimate of $51.00 and a low estimate of $10.35. A 38.75% drop is ...

Detailed price information for Tandem Diabetes Care (TNDM-Q) from The Globe and Mail including charting and trades.

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. resulting from allegations that ...

LOS ANGELES, Oct. 16, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces that ...

Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.